Efficacy of Qianlie Shutong Capsule in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Single-Centre Retrospective Study.

BACKGROUND

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological condition affecting men's health. This study aims to investigate the clinical efficacy of Qianlie Shutong (QLST) capsule in the treatment of CP/CPPS.

METHODS

The medical records of patients with CP/CPPS who were admitted to our hospital from January 2023 to January 2024 were retrospectively analysed. They were divided into observation and control groups according to treatment modality received. The control group received levofloxacin (0.5 g, qd) in combination with tamsulosin hydrochloride (0.2 mg, qd). The observation group received an additional supplementation of QLST capsule (0.4 g, tid) alongside the treatment administered to the control group. Both groups underwent treatment for 28 days. Baseline data and clinical outcomes were compared between the groups, including the National Institute of Health-Chronic Prostatitis Symptom Index (NIH-CPSI), maximum urine flow rate (Qmax), urine volume (UV), prostate-specific extracellular vesicle protein (PSEP) and International Index of Erectile Function-15 (IIEF-15).

RESULTS

A total of 117 patients were enrolled in this study, comprising 60 in the observation group and 57 in the control group. No significant differences in baseline characteristics were found between the two groups (p > 0.05). Before intervention, no significant differences in NIH-CPSI, Qmax, UV, PSEP and IIEF-15 were found between the two groups (p > 0.05). Following intervention, both groups exhibited significant reductions in NIH-CPSI and PSEP, and the levels in the observation group were lower than those in the control group (p < 0.05). Qmax, UV and IIEF-15 increased in both groups, and the levels in the observation group were higher than those in the control group (p < 0.05).

CONCLUSIONS

This study demonstrates that QLST effectively alleviates the clinical symptoms in patients with CP/CPPS, reduces PSEP levels and improves erectile function, supporting its clinical application.